Small molecule activators of the FOXO3 transcription factor

Refoxy Pharma is focused on developing innovative therapies targeting age-related diseases through the modulation of the FOXO3 protein. This protein plays a critical role in maintaining cellular homeostasis and orchestrating responses to various stressors, making it a key player in human health. Unlike traditional drug development approaches that often target single proteins or pathways, Refoxy's strategy aims to leverage FOXO3 as a master regulator, potentially leading to more effective treatments for complex conditions such as fibrotic and cardiovascular diseases. By addressing multiple biological processes simultaneously, the company seeks to enhance healthspan and combat age-related pathologies.

The company has established a robust discovery platform designed to identify and optimize small molecule activators of FOXO3. This platform, known as F.act finder, is built on foundational research by Prof. Wolfgang Link and employs a combination of phenotypic screening and rigorous assessments to ensure specificity and safety. Refoxy's lead therapeutic candidate demonstrates significant anti-fibrotic properties and is being evaluated for its potential in treating Idiopathic Pulmonary Fibrosis (IPF), a serious condition with limited treatment options. Additionally, the platform has yielded several other promising molecules that are currently being assessed for their therapeutic potential across various diseases.

Germany

Refoxy Pharma is a pre-clinical stage biotechnology company developing medicines for the treatment and prevention of aging and aging-associated diseases.

Refoxy Pharma

Company Details